Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA

BACKGROUND: Randomized phase III trials have established the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as first-line treatment for EGFR mutation-positive advanced non–small-cell lung cancer (EGFR Mut+ NSCLC). This retrospective cohort study examined the managemen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS One
Hauptverfasser: Li, Yulin, Appius, Anita, Pattipaka, Thirupathi, Feyereislova, Andrea, Cassidy, Adrian, Ganti, Apar Kishor
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2019
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6319739/
https://ncbi.nlm.nih.gov/pubmed/30608948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0209709
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge